Why the study?
Are oral anti-diabetic agents safe in patients with type 2 diabetes mellitus and cardiovascular diseases?
Are oral anti-diabetic agents safe in patients with type 2 diabetes mellitus and cardiovascular diseases?
This review explores the cardiovascular safety of various oral anti-diabetic agents in patients with type 2 diabetes and cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Offers synthesis of antidiabetic CV safety literature; leaves open need for updated trials in T2DM with CVD.
Cardiovascular disease is the major cause of mortality among patients with type 2 diabetes mellitus, accounting for 60-80% of death in these patients. Despite recent studies demonstrating likely benefit of good glycaemic control in decreasing cardiovascular risk in type 2 DM, there have been lingering concerns about potential adverse cardiovascular effects of insulin secretagogues, specifically sulphonylureas. In this review article, we have tried to explore the issue of safe oral anti-diabetic agents in patients having different cardiovascular diseases. doi: 10.3329/taj.v20i1.3097 TAJ 2007; 20(1): 79-86
No takes yet. Share an insight, caveat, or question.
Haque et al. (1970) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: